Evidence map›Paper›PMID 32694604›Full record

ArticleScientific reports2020

Identification of a unique temporal signature in blood and BAL associated with IPF progression.

Katy C Norman, David N O'Dwyer, Margaret L Salisbury, Katarina M DiLillo, Vibha N Lama, Meng Xia, Stephen J Gurczynski, Eric S White, Kevin R Flaherty, Fernando J Martinez and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Katy C NormanDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109 , USA.
David N O'DwyerDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Margaret L SalisburyDivision of Allergy, Department of Medicine, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Katarina M DiLilloDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109 , USA.
Vibha N LamaDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Meng XiaDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Stephen J GurczynskiDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Eric S WhiteDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Kevin R FlahertyDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Fernando J MartinezDepartment of Internal Medicine, Weill Cornell School of Medicine, New York, NY, USA.
Susan MurrayDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Bethany B MooreDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Kelly B ArnoldDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109 , USA. kbarnold@umich.edu.

Funding

Immunobiology of Lung Injury and FibrosisR35HL144481 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOORE, BETHANY B. · 2019 to 2024
$5.2M
Identification of immune cell-cell communication networks and inflammatory pulmonary microenvironments associated with the progression of COPDR01HL144849 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ARNOLD, KELLY · 2019 to 2023
$1.6M
Host Response, Lung Microbiome, and Clinical Phenotype in Hypersensitivity PneumoniaK23HL141539 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SALISBURY, MARGARET LOUISE · 2019 to 2023
$856k
Toll-like Receptors and Respiratory Microbiota Interactions in Idiopathic PulmonaryR00HL139996 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI O'DWYER, DAVID NOEL · 2020 to 2022
$747k
NHLBI NIH HHS K23 HL141539NHLBI NIH HHS L30 HL138825NHLBI NIH HHS R00 HL139996NHLBI NIH HHS R01 HL144849NHLBI NIH HHS R35 HL144481
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and heterogeneous interstitial lung disease of unknown origin with a low survival rate. There are few treatment options available due to the fact that mechanisms underlying disease progression are not well understood, likely because they arise from dysregulation of complex signaling networks spanning multiple tissue compartments. To better characterize these networks, we used systems-focused data-driven modeling approaches to identify cross-tissue compartment (blood and bronchoalveolar lavage) and temporal proteomic signatures that differentiated IPF progressors and non-progressors. Partial least squares discriminant analysis identified a signature of 54 baseline (week 0) blood and lung proteins that differentiated IPF progression status by the end of 80 weeks of follow-up with 100% cross-validation accuracy. Overall we observed heterogeneous protein expression patterns in progressors compared to more homogenous signatures in non-progressors, and found that non-progressors were enriched for proteomic processes involving regulation of the immune/defense response. We also identified a temporal signature of blood proteins that was significantly different at early and late progressor time points (p < 0.0001), but not present in non-progressors. Overall, this approach can be used to generate new hypothesis for mechanisms associated with IPF progression and could readily be translated to other complex and heterogeneous diseases.

Indexed as

AgedBiomarkersBlood ProteinsBronchoalveolar Lavage FluidDisease ProgressionDisease SusceptibilityFemaleGene ExpressionHumansIdiopathic Pulmonary FibrosisMaleMiddle AgedProtein Interaction MappingProteomicsBiomarkersBlood Proteins

Identifiers

PMID32694604
PMCPMC7374599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.